Cargando…
PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer
Mismatch repair (MMR) analysis in breast cancer may help to inform immunotherapy decisions but it lacks breast-specific guidelines. Unlike in other neoplasms, MMR protein loss shows intra-tumor heterogeneity and it is not mirrored by microsatellite instability in the breast. Additional biomarkers ca...
Autores principales: | Lopez, Gianluca, Noale, Marianna, Corti, Chiara, Gaudioso, Gabriella, Sajjadi, Elham, Venetis, Konstantinos, Gambini, Donatella, Runza, Letterio, Costanza, Jole, Pesenti, Chiara, Grossi, Francesco, Maggi, Stefania, Ferrero, Stefano, Bosari, Silvano, Fusco, Nicola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073136/ https://www.ncbi.nlm.nih.gov/pubmed/32098071 http://dx.doi.org/10.3390/ijms21041461 |
Ejemplares similares
-
Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling
por: Sajjadi, Elham, et al.
Publicado: (2021) -
Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability
por: Fusco, Nicola, et al.
Publicado: (2018) -
PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?
por: Fusco, Nicola, et al.
Publicado: (2020) -
Breast Cancer Systemic Treatments and Upper Limb Lymphedema: A Risk-Assessment Platform Encompassing Tumor-Specific Pathological Features Reveals the Potential Role of Trastuzumab
por: Invernizzi, Marco, et al.
Publicado: (2019) -
Osteoclast-like stromal giant cells in breast cancer likely belong to the spectrum of immunosuppressive tumor-associated macrophages
por: Sajjadi, Elham, et al.
Publicado: (2022)